Exelixis Announces Final Results From Phase 3 Pivotal CABINET Study Evaluating Cabozantinib In Advanced Neuroendocrine Tumors Presented At ESMO 2024 And Published In New England Journal Of Medicine
Portfolio Pulse from Benzinga Newsdesk
Exelixis, Inc. announced final results from the Phase 3 CABINET study, showing cabozantinib significantly improves progression-free survival in advanced neuroendocrine tumors. These results support a supplemental New Drug Application with the FDA.
September 16, 2024 | 12:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Exelixis' cabozantinib demonstrated significant improvement in progression-free survival in advanced neuroendocrine tumors, supporting a supplemental New Drug Application with the FDA.
The positive results from the CABINET study enhance the potential for FDA approval of cabozantinib for advanced neuroendocrine tumors, likely boosting investor confidence and stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100